[Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor].
Knöchel
B
B
Klinik für Innere Med. IV Friedrich-Schiller-Universität Jena.
Luttmann
W
W
Kroegel
C
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000517:prevention & control*; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000517:prevention & control*; D007108:Immune Tolerance / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D018123:Receptors, Interleukin / Q000276:immunology*; D019948:Receptors, Interleukin-4; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018123:Receptors, Interleukin; D019948:Receptors, Interleukin-4; D011994:Recombinant Proteins; D010047:Ovalbumin
Prävention der Entwicklung der allergischen Sofort-reaktion und der Atemwegshyperreagibilität durch Behandlung mit dem löslichen IL-4-Rezeptor in vivo.